Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-12-16Clinical Trial Update: Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease [NA]
A clinical trial evaluating early versus late blood biomarker testing for Alzheimer's disease has been withdrawn, with no results reported.
-
CLINICAL_TRIALS withdrawal · 2025-09-29Clinical Trial Update: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease [Phase 1, Phase 2]
Hope Biosciences' autologous mesenchymal stem cell therapy (HB-adMSCs) trial for Alzheimer disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
A non-interventional pilot study evaluating the role of gut flora in Alzheimer's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Clinical Trial of AGB101 for Mild Cognitive Impairment [Phase 2]
Phase 2 trial of AGB101 for Mild Cognitive Impairment and prodromal Alzheimer's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-27Clinical Trial Update: Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease [Phase 4]
Phase 4 trial evaluating histidine oral supplementation for Alzheimer's disease has been withdrawn; no results are reported.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-04-25Clinical Trial Update: Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) [Phase 1]
A Phase 1 multiple-dose trial of MK-4334 in participants with Alzheimer's disease and mild cognitive impairment has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-17Clinical Trial Update: A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. [Phase 1]
A Phase 1 clinical trial investigating a novel therapeutic target for Alzheimer's disease in adults aged 50-85 was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-01Clinical Trial Update: Effect of Neuronavigated Theta-Burst Transcranial Magnetic Stimulation (TBS) for Early Alzheimer's Disease [NA]
This clinical trial update reports the withdrawal of a study evaluating neuronavigated theta-burst transcranial magnetic stimulation for ear…
-
CLINICAL_TRIALS withdrawal · 2025-01-27Clinical Trial Update: Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study [NA]
A clinical trial investigating brain insulin resistance in Alzheimer’s disease and mild cognitive impairment using intranasal insulin; the s…
-
CLINICAL_TRIALS withdrawal · 2024-11-07Clinical Trial Update: Voice and Swallowing Disorders in Adults With and Without Alzheimer's Disease
The clinical trial NCT06328374 evaluating voice and swallowing disorders in adults with and without Alzheimer’s disease has been withdrawn.
-
EMA withdrawal · 2024-10-23EMA Withdrawn: Memantine LEK (memantine hydrochloride) — Pharmathen S.A.
EMA has withdrawn Memantine LEK (memantine hydrochloride) from the market. The withdrawal affects treatment for Alzheimer's disease.
-
CLINICAL_TRIALS withdrawal · 2024-09-23Clinical Trial Update: Improving Function, Quality of Life, Glycemia in Diabetics With Dementia [Phase 4]
A Phase 4 trial investigating whether improving function, quality of life, and glycemic control in people with diabetes and dementia has bee…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Meaningful Aspects of Health for Adults With Dementia, Their Care Partners and Healthcare Practitioners
The trial NCT06242574 examining meaningful aspects of health for adults with dementia, their care partners and healthcare practitioners has …
-
CLINICAL_TRIALS withdrawal · 2024-05-13Clinical Trial Update: WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease [NA]
A clinical trial evaluating a wearable neuromodulation device for Alzheimer's disease has been withdrawn. The study targeted mild Alzheimer'…
-
CLINICAL_TRIALS withdrawal · 2024-05-03Clinical Trial Update: First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) [Phase 1]
The first-in-human single ascending dose study of FluoroEthylNorMemantine (FENM) by ReST Therapeutics has been withdrawn; the listed conditi…
-
CLINICAL_TRIALS withdrawal · 2023-04-14Clinical Trial Update: A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension [Phase 3]
Phase 3 MRCT of tricaprilin in mild to moderately severe probable Alzheimer's disease was withdrawn.
-
EMA withdrawal · 2022-08-01EMA Application withdrawn: Aduhelm (aducanumab) — Biogen Netherlands B.V.
EMA withdrew the application for Aduhelm (aducanumab) by Biogen Netherlands B.V. for Alzheimer’s disease.
-
CLINICAL_TRIALS withdrawal · 2017-11-24Clinical Trial Update: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease [Phase 1, Phase 2]
A clinical trial evaluating the safety and effects of autologous adipose-derived stromal cells in Alzheimer's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-09Clinical Trial Update: CPC-201 Alzheimer's Disease Type Dementia: PET Study [Phase 2]
The Phase 2 Alzheimer's disease PET study CPC-201 has been withdrawn. Sponsor is Chase Pharmaceuticals Corporation, an affiliate of Allergan…
-
CLINICAL_TRIALS withdrawal · 2017-04-07Clinical Trial Update: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease [Phase 2]
Phase 2 safety study of sargramostim for mild cognitive impairment due to Alzheimer's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-12-13Clinical Trial Update: Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers [Phase 1]
A Phase 1 study investigating the pharmacokinetic interaction between itraconazole and rilapladib in healthy volunteers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-05-03Clinical Trial Update: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease [Phase 3]
A Phase 3 study evaluating two doses of EVP-6124 in Alzheimer's disease was terminated.
-
CLINICAL_TRIALS withdrawal · 2016-02-09Clinical Trial Update: The Role of Mid-Life Adiposity in Functional Brain Connectivity
A clinical trial investigating the effect of mid-life adiposity on functional brain connectivity related to Alzheimer’s disease has been ter…
-
CLINICAL_TRIALS withdrawal · 2016-02-04Clinical Trial Update: Using Hypnotherapy For Dementia & Alzheimer's
A clinical trial studying hypnotherapy for dementia and Alzheimer's disease is no longer available.
-
CLINICAL_TRIALS withdrawal · 2016-01-14Clinical Trial Update: A Composite MR Neuroimaging Marker for Alzheimer's Disease
The clinical trial evaluating a composite MR neuroimaging marker for Alzheimer's disease and related cognitive impairment has been withdrawn…